Travere Therapeutics (TVTX) Competitors $18.37 -0.10 (-0.54%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TVTX vs. ELAN, CYTK, NUVL, GRFS, VKTX, TGTX, KRYS, AXSM, OGN, and ALVOShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), Krystal Biotech (KRYS), Axsome Therapeutics (AXSM), Organon & Co. (OGN), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. Elanco Animal Health Cytokinetics Nuvalent Grifols Viking Therapeutics TG Therapeutics Krystal Biotech Axsome Therapeutics Organon & Co. Alvotech Travere Therapeutics (NASDAQ:TVTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment. Does the MarketBeat Community believe in TVTX or ELAN? Elanco Animal Health received 59 more outperform votes than Travere Therapeutics when rated by MarketBeat users. However, 57.66% of users gave Travere Therapeutics an outperform vote while only 54.55% of users gave Elanco Animal Health an outperform vote. CompanyUnderperformOutperformTravere TherapeuticsOutperform Votes7957.66% Underperform Votes5842.34% Elanco Animal HealthOutperform Votes13854.55% Underperform Votes11545.45% Does the media prefer TVTX or ELAN? In the previous week, Travere Therapeutics had 8 more articles in the media than Elanco Animal Health. MarketBeat recorded 11 mentions for Travere Therapeutics and 3 mentions for Elanco Animal Health. Travere Therapeutics' average media sentiment score of 0.65 beat Elanco Animal Health's score of 0.53 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, TVTX or ELAN? Travere Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Which has better valuation & earnings, TVTX or ELAN? Travere Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Travere Therapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$203.45M7.05-$111.40M-$4.55-4.04Elanco Animal Health$4.45B1.33-$1.23B$0.4030.06 Do analysts recommend TVTX or ELAN? Travere Therapeutics presently has a consensus target price of $24.00, suggesting a potential upside of 30.65%. Elanco Animal Health has a consensus target price of $16.43, suggesting a potential upside of 36.62%. Given Elanco Animal Health's higher probable upside, analysts plainly believe Elanco Animal Health is more favorable than Travere Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.92Elanco Animal Health 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Is TVTX or ELAN more profitable? Elanco Animal Health has a net margin of 4.60% compared to Travere Therapeutics' net margin of -172.75%. Elanco Animal Health's return on equity of 6.78% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-172.75% -537.74% -55.65% Elanco Animal Health 4.60%6.78%3.03% Do institutionals & insiders hold more shares of TVTX or ELAN? 97.5% of Elanco Animal Health shares are held by institutional investors. 3.8% of Travere Therapeutics shares are held by insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryElanco Animal Health beats Travere Therapeutics on 10 of the 18 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44B$6.58B$5.36B$9.11BDividend YieldN/A2.95%5.13%4.03%P/E Ratio-4.049.8389.4717.33Price / Sales7.05307.311,263.57137.15Price / CashN/A61.4443.7535.97Price / Book6.886.055.324.80Net Income-$111.40M$154.62M$122.60M$224.91M7 Day Performance1.55%-1.68%0.69%1.77%1 Month Performance7.18%-2.35%1.55%2.22%1 Year Performance99.02%1.02%27.25%20.67% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics2.855 of 5 stars$18.37-0.5%$24.00+30.6%+99.0%$1.44B$203.45M-4.04460Analyst ForecastAnalyst RevisionELANElanco Animal Health4.415 of 5 stars$11.59+1.4%$16.43+41.7%-18.8%$5.73B$4.45B28.989,800CYTKCytokinetics4.313 of 5 stars$46.38-0.5%$83.64+80.3%-46.6%$5.47B$7.53M-8.62250Analyst ForecastNUVLNuvalent1.793 of 5 stars$71.99-6.0%$112.36+56.1%+2.7%$5.12BN/A-20.7540Analyst ForecastInsider TradeNews CoverageGRFSGrifols2.0473 of 5 stars$7.25-0.5%N/A+7.2%$4.98B$7.01B5.9426,300Positive NewsGap DownVKTXViking Therapeutics3.922 of 5 stars$38.78-1.3%$106.75+175.3%+52.4%$4.32BN/A-41.7020Analyst ForecastGap DownTGTXTG Therapeutics4.4921 of 5 stars$27.60-4.4%$40.67+47.3%+93.1%$4.30B$264.79M-275.97290Analyst ForecastAnalyst RevisionNews CoverageKRYSKrystal Biotech4.8312 of 5 stars$148.67-2.8%$206.67+39.0%+17.8%$4.28B$241.52M83.99229Short Interest ↓AXSMAxsome Therapeutics4.6334 of 5 stars$88.13+10.1%$129.43+46.9%+7.5%$4.27B$338.46M-13.50380Analyst RevisionGap UpOGNOrganon & Co.4.8105 of 5 stars$15.60-1.6%$21.33+36.8%-0.8%$4.02B$6.41B3.1010,000Positive NewsALVOAlvotech2.552 of 5 stars$13.15-2.7%$18.00+36.9%+7.4%$3.96B$391.87M-7.111,026Positive News Related Companies and Tools Related Companies Elanco Animal Health Competitors Cytokinetics Competitors Nuvalent Competitors Grifols Competitors Viking Therapeutics Competitors TG Therapeutics Competitors Krystal Biotech Competitors Axsome Therapeutics Competitors Organon & Co. Competitors Alvotech Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TVTX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
